Updated: Feb 10
The final three webinars in our 2020 webinar series were delivered by Dr Melyssa Roy and Professor Paul Hansen (University of Otago); Dr Yeri Kim and Dr Melissa Barry (ACC); and Carsten Schousboe (Roche Products):
Thursday, 10 September 2020, 10-11 am: Dr Melyssa Roy, Department of Preventive and Social Medicine, University of Otago. ICU prioritisation in the time of Covid: Who gets a ventilator?
Thursday, 8 October 2020, 10-11 am: Yeri Kim, Dr Melissa Barry, ACC. The ACC Impact Investment Fund.
Thursday, 5 November 2020, 10-11.15 am: Carsten Schousboe, Roche Products. A primer for the HTA community on Next Generation Sequencing.
Please see this post for upcoming webinars in our 2021 series.
Thursday, 10 September 2020
Dr Melyssa Roy, Prof Paul Hansen
Department of Surgical Sciences, University of Otago
ICU prioritisation in the time of Covid: Who gets a ventilator?
The Covid-19 pandemic is generating unprecedented demand for intensive care beds and ventilators around the world. Prioritising Covid patients for admission to intensive care units (ICUs) to receive ventilatory support often relies on clinical judgement alone. When ICUs become overwhelmed, valid, transparent and pragmatic prioritisation tools are urgently needed.
Melyssa and Paul presented the findings from an expert group from intensive care, nursing, Māori health, infectious diseases and neonatology who utilised Multi-Criteria Decision Analysis (MCDA) methods to specify criteria, and weights representing their relative importance, for prioritizing Covid-19 patients for ICU, and discussed the ethical principles underlying these decisions.
Thursday, 8 October 2020
Yeri Kim, Dr Melissa Barry
The ACC Impact Investment Fund
ACC plays a critical role in supporting and improving the wellbeing and health of New Zealanders. The ACC’s new Impact Investment Fund is the first of its kind in the New Zealand market and reflects the combination of our unique role in injury prevention with our investment responsibilities. The new Fund has two objectives; to deliver the best possible risk-adjusted return to our $45 billion investment fund, while driving social improvements that align with our core purpose of injury prevention, care, and recovery for the benefit of all New Zealanders. Through the Fund, we are looking for opportunities to invest in and partner with companies
who support and improve the health, safety, and the wellbeing of New Zealanders.
Yeri and Melissa gave an overview of the scope of the impact investment fund followed by a discussion on impact investment practices to assess social outcomes.
Thursday, 5 November 2020
A primer for the HTA community on Next Generation Sequencing
Carsten outlined three major developments in diagnostic technology for cancer management. He looked at some of the implications and options from a Health Technology Assessment perspective with a focus on how the HTA community can contribute to the debate around access. He also shared some thoughts about the options we have when choosing how to evolve.